{
  "_id": "722dc1a6d3ded816551b019e44f61a12af3c7aab2a8b2ef29162afad60e435a0",
  "feed": "market-watch",
  "title": "Market rout casts cloud over biggest IPO of the year as at least two deals are pulled during brutal selloff; AIG unit Corebridge Financial priced at low end of range after massive selloff",
  "text": "<p>And cancer-focused biotech Elicio Therapeutics pulled its $40 million offering, according to Renaissance.</p><p>The decisions came as the Dow Jones Industrial Average DJIA shed 1,300 points Tuesday to mark itsworst one-day performance since June 11 of 2020,following an unexpectedly hot consumer-price inflation reading for August.</p><p>The S&amp;P 500 shed 4.3%, while the Nasdaq Composite COMP fell 5.2% in a broad-based selloff. All 11 S&amp;P 500 sectors finished in the red after the August consumer-price index, or CPI, rose 0.1% in August. Though the year-over-year rate slowed to 8.3% from 8.5% in July, economists had been looking for a monthly fall of 0.1% that would bring the year-over-year rate down to 8%.</p><p>Corebridge priced its deal late Wednesday at $21 a share, the low end of a range that topped at $24 a share. Corebridge offered 80 million shares to raise the most of any deal in this year's frozen market. It had hoped to raise as much as $1.8 billion.</p><p>For more, see:  This AIG spinoff is the biggest IPO of the year at just $1.8 billion in a sign of the deep freeze in new offerings</p><p>To be sure, Corebridge had some points in its favor, not least being that it's profitable and has delivered solid growth. Corebridge had net income of $6.4 billion in the first half of the year on revenue of $16 billion, according to its filing documents. That was up from net income of $2.8 billion in the year-earlier period, on revenue of $11.02 billion.</p><p>The company is planning to pay quarterly dividends, offering a 4.1% annualized yield at the midpoint of its range, according to Renaissance co-Founder and CEO Bill Smith. It had $358 billion in client assets as of June 30.</p><p>The deal CRBG had a strong roster of underwriters at 43 banks, with JPMorgan acting as lead. It will start trading on the New York Stock Exchange later Thursday under the ticker \"CRBG.\"</p><p>Linkbancorp Inc. LNKB, which operates Pennsylvania-based The Gratz Bank, priced its public offering on Tuesday at $7.50 a share, below its price range of $8.00 to $9.50. That offering was an uplisting to the Nasdaq from the OTC market. The stock was up 2.4% in recent trades.</p><p>Also on the docket Wednesday was biotech Third Harmonic Bio. THRD The company specializes in treatments for allergic and inflammatory diseases. It priced its IPO at $17 a share, the midpoint of a $16 to $18 price range. The company upsized the deal to 10.9 million shares from an earlier plan to offer just 9 million, raising $185.3 million. The stock will start trading on Nasdaq later Thursday, under the ticker \"THRD.\"</p><p>The Renaissance IPO ETF IPO has fallen 43% in the year to date, while the S&amp;P 500 SPX has fallen 17%.</p><p>Read now: You bought. They sold. Meet some of the insiders who unloaded $35 billion in stock amid the tech IPO bonanza before it tanked.</p><p>Market rout casts cloud over biggest IPO of the year as at least two deals are pulled during brutal selloff</p>",
  "published": "2022-09-15T11:48:00.000Z",
  "tags": [
    {
      "id": "US46625H1005",
      "name": "JPMorgan Chase & Co.",
      "offsets": [
        {
          "start": 1733,
          "end": 1741
        }
      ],
      "nexusId": "10009914"
    }
  ]
}